Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
about
Rational Polytherapy with Antiepileptic Drugs.Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients.Refractory epilepsy: mechanisms and solutions.Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.Exploring the latest avenues for antiepileptic drug discovery and development.Interactions of propofol and remifentanil on bispectral index under 66% N(2)O: analysis by dose-effect curve, isobologram, and combination indexInteractions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock.Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.Effects of amlodipine, diltiazem, and verapamil on the anticonvulsant action of topiramate against maximal electroshock-induced seizures in mice.Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis.Involvement of GABAergic and glutamatergic systems in the anticonvulsant activity of 3-alkynyl selenophene in 21 day-old rats.How to get the answer to nearly everything: using the internet for epilepsy research.Interactions of Mexiletine with Novel Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis
P2860
Q33664046-187B2C42-6449-4A6A-B679-12F314679EB7Q33868103-F8E7D98C-3D46-44B4-B255-D23DE68A21B9Q36419584-C399F854-3B5E-41F2-BC54-0D6AB8DF1566Q36754801-342CBC2E-0D28-4AD2-817D-80D6E6CD8580Q38367761-016E3BFE-32B1-4478-938D-ECB6C632F402Q38754189-644B6EE3-5FAF-4901-867C-4673BEBF9C74Q41950579-97BA87D2-249F-44A6-BC3B-5AC408B9119BQ45132932-21BE73CF-FD96-4CD9-AEA1-45C3E85A2427Q45282313-9555CF73-2DD5-4C37-839B-F2095838C7A9Q46640269-4D6BB8BD-FA86-4652-B908-717F639E2F24Q46792871-0156490B-73EE-44AD-A440-DD87BAE2F0AAQ46897460-07B7536A-B330-4380-84A2-C8FE020F1A7AQ48105985-00628602-91EE-4289-AD3D-54D8985EFF66Q48650701-8E309308-6385-425B-BD2C-B9CA89D4F9B5Q53184071-2912E14A-2C61-45CE-B6FF-D2CBA02FA4FFQ58772300-040FD5CF-0E9A-4270-A7AF-9573F28B4F2C
P2860
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Preclinical profile of combina ...... s: an isobolographic analysis.
@en
Preclinical profile of combina ...... s: an isobolographic analysis.
@nl
type
label
Preclinical profile of combina ...... s: an isobolographic analysis.
@en
Preclinical profile of combina ...... s: an isobolographic analysis.
@nl
prefLabel
Preclinical profile of combina ...... s: an isobolographic analysis.
@en
Preclinical profile of combina ...... s: an isobolographic analysis.
@nl
P2860
P1433
P1476
Preclinical profile of combina ...... s: an isobolographic analysis.
@en
P2093
Stanislaw J Czuczwar
P2860
P304
P356
10.1111/J.0013-9580.2004.05104.X
P577
2004-08-01T00:00:00Z